Trial Profile
A Phase IIA Trial of Two Schedules of Perifosine.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2018
Price :
$35
*
At a glance
- Drugs Perifosine (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors AEterna Zentaris Inc
- 04 Mar 2013 Additional lead trial centre added as reported by ClinicalTrials.gov record.
- 16 Oct 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 16 Oct 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.